Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
May 16 2022 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, announced today that AVISE® CTD and
AVISE® Lupus are a contracted covered service with Alivio Health,
providing enhanced care to their 150,000 members. The agreement
also makes AVISE® diagnostic testing available as an in-network
benefit.
“We are grateful to be partnering with Alivio Health. This
partnership provides Alivio Health members and providers a timely
and accurate differential diagnosis to improve outcomes for complex
autoimmune diseases, including Systemic Lupus Erythematosus (SLE),”
said Ron Rocca, Exagen’s President and CEO. “Lupus is tricky to
diagnose, and it currently takes an average of six years before
being confirmed with the disease. That timeframe could lead to
irreversible organ damage, since prompt treatment is key to
managing symptoms. Providing greater access to accurate testing
means a better chance of catching lupus early.”
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus.
For more information, please visit Exagen.com and follow
@ExagenInc on Twitter.
About Alivio Health
Alivio Health is a national genetic benefit solutions company
committed to providing access to a comprehensive suite of molecular
diagnostics enabling actionable insights for patients and their
physicians. The constant and rapid expansion of genetic services
has left laboratories and payers of healthcare incessantly
navigating challenges around medical policy, coverage, and
reimbursement. Alivio Health, through its comprehensive nationwide
network of genetic laboratories, is facilitating access to the
right test at the right time for employers and their employees. For
more information, visit alivio.health.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen's
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements regarding the expected
benefits of the positive medical policy coverage for the AVISE CTD
and AVISE Lupus tests with Alivio Health, including the
availability and expected use of the AVISE CTD and AVISE Lupus
tests through the Alivio Health Care Network, and any potential for
increased use of the AVISE CTD and AVISE Lupus laboratory tests.
The inclusion of forward-looking statements should not be regarded
as a representation by Exagen that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Exagen’s business, including, without limitation: the COVID-19
pandemic may continue to adversely affect its business, financial
condition and results of operations, including as a result of
slowdown in its operations as well as those of its suppliers and
courier services, impeding patient movement and interruptions to
healthcare services causing a decrease in test volumes, disruptions
to the supply chain of material needed for its tests, causing an
increase in cost per test, its sales and commercialization
activities and its ability to receive specimens and perform or
deliver the results from its tests, delays in reimbursement and
coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payors and others in the
medical community; Exagen’s ability to successfully execute on its
business strategies; third-party payors not providing coverage and
adequate reimbursement for Exagen’s testing products or promoted
therapeutics, including Exagen’s ability to collect funds due;
Exagen’s ability to obtain and maintain intellectual property
protection for its testing products; regulatory developments
affecting Exagen’s business; and other risks described in Exagen’s
prior press releases and the company’s filings with the Securities
and Exchange Commission (“SEC”), including under the heading “Risk
Factors” in Exagen’s Annual Report on Form 10-K for the year ended
December 31, 2021 and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Exagen
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024